Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

NCT03646617 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

RADIATION: Hypofractionated Radiation Therapy (HFRT)
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

[object Object]